Printed Pages: 01 **Sub Code: BP810ET**

Paper Id: 2 3 1 3 1 1 **Roll No.** | | | | | | | | | | |

B PHARM

(SEM VIII) THEORY EXAMINATION 2022-23

EXPERIMENTAL PHARMACOLOGY

Time: 3 Hours ***Total Marks: 75***

Note: 1. Attempt all Sections. If require any missing data; then choose suitably.

SECTION A

1. Attempt *all* questions in brief. 2x 10 = 20

(a) Write full name of CPCSEA and OECD.

(b) Enlist examples of transgenic and mutant animals.

(c) What do you understand by negative control and positive control in animal grouping?

(d) State any two preclinical screening animal models for anti- inflammatory activity.

(e) Explain *In vivo* and *In vitro* methods in preclinical screening.

(f) Define research design.

(g) What is research hypothesis?

(h) Write any two types of graphical representation of data.

(i) Outline any two preclinical screening models for anti-epilepticagent.

(j) Enlist any two tests for a hypotheses testing.

SECTION B

2. Attempt any *two* parts of the following: 10 x 2 = 20

(a) Describe the method for production, maintenance and applications of transgenic animals.

(b) How will you perform preclinical screening of antipyretic and analgesic agents via *in vivo* and *in vitro* models?

(c) Explain in detail about data and is graphical representation.

SECTION C

3. Attempt any *five* parts of the following: 5 x 7 = 35

(a) State any two screening methods for antihypertensive drugs.

(b) Discuss about In-vitro screening method for anticancer agent.

(c) Illustrate the screening methods for anti -emetic and anti-diarrhoeal agents?

(d) Explain the anesthesia and euthanasia of experimental animals.

(e) How will you perform preclinical screening for skeletal muscle relaxant agent? Describe any two models.

(f) Explain preclinical screening models for anti-diabetic agents.

(g) Write in detail about preclinical screening models for Diuretics, nootropics.

QP23DP1_290 | 11-01-2023 09:04:59 | 117.55.242.132

QP23DP1_290 | 11-01-2023 09:04:59 | 117.55.242.132